Dr. Ferrajoli on the Benefits and Limitations of Frontline Fixed-Duration Therapy in CLL

Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.

Related Keywords

Texas ,United States ,Alessandra Ferrajoli ,Department Of Leukemia ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,Olive State ,Science Summit ,Cll ,Fixed Duration Therapy ,Soho ,